These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Interferon therapy of multiple sclerosis]. Jensen D Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses]. Svenningsson A; Andersson M; Olsson T Lakartidningen; 1998 Dec; 95(49):5623-7, 5630. PubMed ID: 9863300 [TBL] [Abstract][Full Text] [Related]
8. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872 [TBL] [Abstract][Full Text] [Related]
9. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547 [TBL] [Abstract][Full Text] [Related]
10. Issues in pharmaceutical lotteries: the case of interferon beta-1b. Manocchia M; Lasagna L Clin Pharmacol Ther; 1997 Sep; 62(3):241-7. PubMed ID: 9333099 [No Abstract] [Full Text] [Related]
11. Desensitization in interferon-beta1a allergy: a case report. Fusun Kalpaklioglu A; Baccioglu Kavut A; Erdemoglu AK Int Arch Allergy Immunol; 2009; 149(2):178-80. PubMed ID: 19127077 [TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771 [TBL] [Abstract][Full Text] [Related]
13. [Multiple sclerosis: current therapeutic strategies]. Chofflon M Rev Med Suisse Romande; 2003 Jan; 123(1):27-32. PubMed ID: 15095724 [No Abstract] [Full Text] [Related]
14. The challenge of follow-on biologics for treatment of multiple sclerosis. Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456 [TBL] [Abstract][Full Text] [Related]
15. The challenge of follow-on biologics for treatment of multiple sclerosis. Rivera VM Neurology; 2010 Mar; 74(10):864. PubMed ID: 20211915 [No Abstract] [Full Text] [Related]
16. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al]. Labetouelle M J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406 [No Abstract] [Full Text] [Related]
17. Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection. Tan FU; Cetinkaya H; Erden E; Ulkatan S; Aydin N Hepatogastroenterology; 2002; 49(48):1686-7. PubMed ID: 12397766 [TBL] [Abstract][Full Text] [Related]
18. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394 [TBL] [Abstract][Full Text] [Related]